close icon-linkedin icon-twitter icon-facebook icon-mail icon-google-plus icon-search icon-phone icon-instagram
What are you looking for?
News 7 Oct 2021

NLO advises Precirix in major trial milestone

Caroline Pallard and her team have been assisting Belgian biotech company Precirix. Precirix develops precision radiopharmaceuticals in oncology. On 6 October the company announced a major milestone of its lead therapeutic asset; it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer.

Worldwide, >1.6 m cases of breast cancer and >1.2m cases of gastric cancer are diagnosed annually, of which >20% are HER2-positive. At this moment, there are no approved HER2 targeting radiopharmaceuticals and CAM-H2 is the lead candidate in therapeutic development. 

About Precirix

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. 

The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment. 

Read more: Precirix dosed first patients in Phase I/II clinical study | Precirix